Form 4: TriSalus Life Sciences Director Acquires Stock Options

Kerry R. Hicks, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares on August 13, 2024.

Summary

• On August 13, 2024, Kerry R. Hicks, a director of TriSalus Life Sciences, acquired stock options for 15,000 shares.
• The exercise price of the options is $5.75.
• The options vest fully on the one-year anniversary of the grant date or on the date of the Issuer's next annual stockholder meeting, whichever comes first, subject to continued service with the Issuer.
• The options expire on August 12, 2034.
• Following the transaction, Hicks directly owns 15,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction, but a director acquiring stock options can be seen as a mildly positive signal.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on continued service with the Issuer.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers to receive stock options as part of their compensation.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotech and pharmaceutical industries.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and company performance.
• Comparable companies like Exact Sciences or Guardant Health also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates